Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer

Trial Profile

Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin
  • Indications Adenocarcinoma; Oesophageal cancer
  • Focus Adverse reactions
  • Acronyms SOX
  • Most Recent Events

    • 26 Jul 2016 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.
    • 26 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2017.
    • 02 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top